GDTC (CytoMed Therapeutics) Cash per Share : $0.42 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). CytoMed Therapeutics's Cash per Share for the quarter that ended in Jun. 2024 was $0.42.

CytoMed Therapeutics Cash per Share Historical Data

The historical data trend for CytoMed Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics Cash per Share Chart

CytoMed Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash per Share

0.06

0.17

0.11

0.59

CytoMed Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash per Share	Get a 7-Day Free Trial			0.10	0.11	0.67	0.59	0.42

CytoMed Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

CytoMed Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	6.752	/	11.53
	=	0.59

CytoMed Therapeutics's Cash per Share for the quarter that ended in Jun. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	4.788	/	11.54
	=	0.41

CytoMed Therapeutics (NAS:GDTC) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

CytoMed Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

F98:Germany

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Executives

Chee Kong Choo	director, 10 percent owner	COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng	director, officer: CSO and CMO	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang	10 percent owner	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan	director, officer: Chief Operating Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd	10 percent owner	18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee	director, officer: Chief Clinical Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh	director	1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544